Gilead has repurchased $2.2 billion in stock

Gilead Sciences Inc. said Wednesday it has repurchased $2.2 billion worth of its stock through Aug. 31 under its $5 billion buyback program. (AP, 9:44 a.m.)

CEO says he would sell Genzyme if price is right

Henri A. Termeer, the battle-scarred chief executive of Genzyme Corp., acknowledged for the first time yesterday that he is open to selling the Cambridge biotechnology company, but not for the $69-a-share price offered by France’s Sanofi-Aventis SA. (Boston Globe, 2:15 a.m.)

For CEO, ‘fair value’ is the key

Genzyme Corp.’s chief executive, Henri A. Termeer, broke his silence yesterday about an $18.5 billion offer from French drug maker Sanofi-Aventis SA to buy the pioneering Cambridge biotechnology company. (Boston Globe, 8/31/10)

Genzyme says no to Sanofi’s $18.5b offer

Genzyme Corp. swiftly rejected an $18.5 billion takeover bid by Sanofi-Aventis AG yesterday, setting the stage for a protracted tug of war between the two drug makers, with the fate of the state’s biggest biotechnology company hanging in the balance. (Boston Globe, 8/31/10)

Genzyme rejects Sanofi-Aventis offer

Biotechnology company Genzyme Corp. said Monday it rejected Sanofi-Aventis SA's $18.5 billion buyout offer because it undervalues the company. (AP, 8/30/10)